Press Release Summary:
GenScript’s new AmMag™ SA semi-automatic purification instrument accelerates and simplifies protein and antibody purification. This instrument reduces the purification process from days to hours. It uses the speed and high binding capacity of magnetic beads with high throughput for larger sample volumes, allowing researchers to purify up to 50 ml samples while keeping a low endotoxin environment.
Original Press Release:
GenScript Launches Novel Technology Licensed from Amgen for Accelerating Protein and Antibody Purification
AmMag SA magnetic purification system first to offer high throughput of large samples, accelerating early stage drug development
SAN DIEGO, Jan. 14, 2019 /PRNewswire/ -- GenScript®, the world's leading gene synthesis provider, announced today at PepTalk that it has launched the AmMag™ SA semi-automatic purification instrument, a novel technology that accelerates and simplifies protein and antibody purification, reducing the process from days to hours. The AmMag SA, developed under an exclusive license agreement with Amgen, combines the speed and high binding capacity of magnetic beads with high throughput for larger sample volumes, enabling researchers for the first time to purify up to 50 ml samples while maintaining a low endotoxin environment.
"Traditional purification instruments operate at a very low speed. Their throughput is limited to the 'one filtered sample at a time' mode of operation, rendering purification a painstakingly slow process," said GenScript Marketing Director Roumen Bogoev. "The AmMag SA purification instrument produces similar results to traditional methods at a fraction of the time, offering organizations a new tool for accelerating the drug development process and ultimately bringing life-saving medications to market more quickly."
The AmMag SA is used in combination with the AmMag protein A beads, which are coated with a recombinant protein A that is resistant to alkaline washes. These are the only magnetic beads on the market that can be sterilized by alkaline washes prior to adding to cell culture, thereby maintaining stability. The instrument also has a built-in ultra-violet light used to sterilize it before use, as well as programs to automatically clear all the piping materials to maintain a low endotoxin level environment.
"New ways of purifying proteins are critical to accelerating the drug discovery process - traditional chromatography has simply become too inefficient," said John Kawooya PhD, director of biologics optimization at Amgen. "We are excited to start using the AmMag SA in our own development program."
The AmMag SA is available now. To learn more about the product, register for an educational webinar here, or visit GenScript at Booth #303 at PepTalk from Jan. 14-18.
GenScript is a leading contract research organization providing gene, peptide, protein, CRISPR, and antibody reagents to scientists in over 100 countries worldwide. Since its foundation in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science and translational biomedical research, as well as early stage pharmaceutical development. With a mission to improve the health of mankind and nature through biotechnology, the company has developed the best-in-class capacity and capability for producing biological reagents in order to Make Research Easy for all scientists. For more information, visit www.genscript.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/genscript-launches-novel-technology-licensed-from-amgen-for-accelerating-protein-and-antibody-purification-300777411.html
CONTACT: Corporate: Sally Wang, Chief Operating Officer, GenScript, 732.885.9188 ext. 111, firstname.lastname@example.org; Media: Susan Thomas, Principal, Endpoint Communications, (619) 540-9195, email@example.com
Web Site: https://www.genscript.com